Buckland P R, O'Donovan M C, McGuffin P
Department of Psychological Medicine, University of Wales College of Medicine, Heath Park, Cardiff, U.K.
Neuropharmacology. 1993 Sep;32(9):901-7. doi: 10.1016/0028-3908(93)90146-t.
Chronic treatment (32 days) with sulpiride (100 mg/kg/day) up-regulated rat brain dopamine D3 receptor mRNA levels by 4-fold but had no effect on the mRNA levels encoding the dopamine D1A, D1B or D2 receptors or the enzymes tyrosine hydroxylase and aromatic amino acid decarboxylase as measured by multiprobe oligonucleotide solution hybridisation. Clozapine (30 mg/kg/day) increased D3 receptor mRNA levels by 5-fold after 4 days, the level dropping to basal after 32 days and also increased D1B mRNA levels by 0.5-fold in a similar pattern. Clozapine did not affect any other dopamine receptors or the synthesising enzyme mRNA levels. We have previously shown that the typical antipsychotics haloperidol and loxapine also increased the mRNA levels of the dopamine D3 receptor and these results suggest that up-regulation of dopamine D3 receptor mRNA may be associated with the therapeutic action of antipsychotic drugs.
舒必利(100毫克/千克/天)进行慢性治疗(32天)使大鼠脑多巴胺D3受体mRNA水平上调了4倍,但通过多探针寡核苷酸溶液杂交检测发现,对编码多巴胺D1A、D1B或D2受体的mRNA水平以及酪氨酸羟化酶和芳香族氨基酸脱羧酶没有影响。氯氮平(30毫克/千克/天)在4天后使D3受体mRNA水平增加了5倍,32天后该水平降至基础水平,并且以类似模式使D1B mRNA水平增加了0.5倍。氯氮平不影响任何其他多巴胺受体或合成酶mRNA水平。我们之前已经表明,典型抗精神病药物氟哌啶醇和洛沙平也增加了多巴胺D3受体的mRNA水平,这些结果表明多巴胺D3受体mRNA的上调可能与抗精神病药物的治疗作用有关。